All inspectors · Key sources (PDF) · Antithrombotics sheet (PDF)
The Antithrombotic Therapy Around PCI one-pagerOpen it in a new tab

The patient in front of you

Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. It is day 2 and she is going home today.

This page helps you decide: Plan to stop aspirin after a short course and continue ticagrelor alone?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mrs. K. at discharge, TWILIGHT supports aspirin plus ticagrelor for 3 months and then ticagrelor alone if she reaches 3 months without a bleed or ischemic event: about one clinically relevant bleed avoided for every 32 patients over the next year, with death, MI or stroke no higher. It does not support stopping aspirin on day 2, and once she needs an anticoagulant it no longer describes her. On the one-pager it sits on page 2, in the “Shorter DAPT — what the trials showed” box.